Arcutis Biotherapeutics Inc (ARQT) is now in the Overvalued zone, suggesting that its current forward PS ratio of 8.08 is considered Overvalued compared with the five-year average of -7.48. The fair price of Arcutis Biotherapeutics Inc (ARQT) is between 14.04 to 19.75 according to relative valuation method. Compared to the current price of 24.76 USD , Arcutis Biotherapeutics Inc By Overvalued By 25.39%.

Relative Value

Fair Zone

14.04-19.75

Current Price：24.76

25.39%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Arcutis Biotherapeutics Inc (ARQT) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Arcutis Biotherapeutics Inc (ARQT) has a current Price-to-Book (P/B) ratio of 22.07. Compared to its 3-year average P/B ratio of 8.68, the current P/B ratio is approximately 154.15% higher. Relative to its 5-year average P/B ratio of 6.64, the current P/B ratio is about 232.48% higher. Arcutis Biotherapeutics Inc (ARQT) has a Forward Free Cash Flow (FCF) yield of approximately -0.94%. Compared to its 3-year average FCF yield of -30.15%, the current FCF yield is approximately -96.90% lower. Relative to its 5-year average FCF yield of -24.71%, the current FCF yield is about -96.21% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ARQT competitors is 3.78, providing a benchmark for relative valuation. Arcutis Biotherapeutics Inc Corp (ARQT.O) exhibits a P/S ratio of 8.08, which is 113.83% above the industry average. Given its robust revenue growth of 81.48%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ARQT increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ARQT in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ARQT currently overvalued or undervalued?

Arcutis Biotherapeutics Inc (ARQT) is now in the Overvalued zone, suggesting that its current forward PS ratio of 8.08 is considered Overvalued compared with the five-year average of -7.48. The fair price of Arcutis Biotherapeutics Inc (ARQT) is between 14.04 to 19.75 according to relative valuation method. Compared to the current price of 24.76 USD, Arcutis Biotherapeutics Inc is Overvalued By 25.39%.

What is Arcutis Biotherapeutics Inc (ARQT) fair value?

ARQT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Arcutis Biotherapeutics Inc (ARQT) is between 14.04 to 19.75 according to relative valuation method.

How does ARQT's valuation metrics compare to the industry average?

The average P/S ratio for ARQT's competitors is 3.78, providing a benchmark for relative valuation. Arcutis Biotherapeutics Inc Corp (ARQT) exhibits a P/S ratio of 8.08, which is 113.83% above the industry average. Given its robust revenue growth of 81.48%, this premium appears sustainable.

What is the current P/B ratio for Arcutis Biotherapeutics Inc (ARQT) as of Mar 02 2026?

As of Mar 02 2026, Arcutis Biotherapeutics Inc (ARQT) has a P/B ratio of 22.07. This indicates that the market values ARQT at 22.07 times its book value.

What is the current FCF Yield for Arcutis Biotherapeutics Inc (ARQT) as of Mar 02 2026?

As of Mar 02 2026, Arcutis Biotherapeutics Inc (ARQT) has a FCF Yield of -0.94%. This means that for every dollar of Arcutis Biotherapeutics Inc's market capitalization, the company generates -0.94 cents in free cash flow.

What is the current Forward P/E ratio for Arcutis Biotherapeutics Inc (ARQT) as of Mar 02 2026?

As of Mar 02 2026, Arcutis Biotherapeutics Inc (ARQT) has a Forward P/E ratio of 76.52. This means the market is willing to pay $76.52 for every dollar of Arcutis Biotherapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Arcutis Biotherapeutics Inc (ARQT) as of Mar 02 2026?

As of Mar 02 2026, Arcutis Biotherapeutics Inc (ARQT) has a Forward P/S ratio of 8.08. This means the market is valuing ARQT at $8.08 for every dollar of expected revenue over the next 12 months.

ARQT Valuation